Project Grant R01HL185054
Award Date 7/6/26
Completion Date 4/30/30
Dollars Obligated $769K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94305, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Stanford University a Project Grant of $159,512 under the Cardiovascular Diseases Research program (CFDA 93.837) effective December 1, 2025, with completion targeted for May 1, 2026. This grant supports research into amelioration of cardiac fibrosis using diverse cell village human cardiac organoids. The project focuses on developing and validating therapeutic approaches to combat fibroblast activation, a...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $770,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective April 1, 2026, with a completion date of January 31, 2033. The grant supports a multidisciplinary research initiative titled "Unraveling Endothelial-Cardiomyocyte Crosstalk in Cardiomyopathy: An Integrated Multimodal Approach," conducted at Stanford's Palo Alto,...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $2.34 million Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective May 1, 2026, through January 31, 2028. The award funds research into cardiomyocyte phenotype and perinuclear phospholamban compartmentalization, with the objective of elucidating novel calcium (Ca2+) signaling mechanisms that regulate pathological cardiac remodeling and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $410,449 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning August 1, 2025, with a completion date of July 31, 2027. This grant supports the development of novel synthetic biology strategies to enhance cell-based therapies for peripheral arterial disease (PAD), a condition affecting over 8 million Americans. The research will...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a Project Grant of $769,846.00, effective July 1, 2026 through March 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development and application of an integrative genomics toolkit designed to computationally predict and experimentally validate sequence edits to regulatory DNA (enhancers and promoters) that reprogram gene...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $768,912 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective July 15, 2026, with completion targeted for April 30, 2031. The award funds research to identify and validate genetic variants associated with cardiac differentiation and congenital heart disease (CHD). The project integrates artificial intelligence with genome engineering to...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Stanford University $323,136 under the Cardiovascular Diseases Research program (CFDA 93.837) for the project "Dissecting Lung Spatial-Biological Niches in Early Fibrogenesis," effective September 1, 2025 through August 31, 2026. This Project Grant supports research aimed at elucidating the biological mechanisms driving early-stage lung fibrosis in interstitial lung diseases (ILDs), which affect...
- Federal Grant Award Summary The Leland Stanford Junior University received a $773,843 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 19, 2025, with a completion date of May 31, 2029. The award funds research to develop a targeted therapy for immunotherapy-induced myocarditis (ICIM), a life-threatening cardiac inflammation that occurs as a side effect of immune checkpoint...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $160,818 to The Leland Stanford Junior University, effective August 1, 2025 through July 31, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project aims to identify druggable genetic factors underlying radiation-induced heart disease (RIHD) by establishing a cell village comprising 96 human induced pluripotent stem cell (iPSC) lines derived...